Operating Data

GW Pharmaceuticals Plc

GW Pharmaceuticals Plc (GWPH)

108.48 €
-0.52 (-0.48%)

Year
A/P
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 12.74311.337,609.91186,009.884,546,657.99111,134,415.95
Revenue (%)
EBITDA -286.27-109.18-86,851.94-2,122,930.71-51,891,007.65-1,268,377,089.18
EBITDA (%)
EBIT -288.80-118.43-87,721.76-2,144,191.64-52,410,690.66-1,281,079,752.93
EBIT (%)
Depreciation 2.539.25869.8121,260.93519,683.0112,702,663.74
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)